mim8
Selected indexed studies
- A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice. (Blood, 2021) [PMID:34077951]
- FRONTIER1: a partially randomized phase 2 study assessing the safety, pharmacokinetics, and pharmacodynamics of Mim8, a factor VIIIa mimetic. (J Thromb Haemost, 2024) [PMID:38142846]
- Mim8, a novel factor VIIIa mimetic bispecific antibody, shows favorable safety and pharmacokinetics in healthy adults. (Res Pract Thromb Haemost, 2023) [PMID:37745159]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice. (2021) pubmed
- FRONTIER1: a partially randomized phase 2 study assessing the safety, pharmacokinetics, and pharmacodynamics of Mim8, a factor VIIIa mimetic. (2024) pubmed
- Mim8, a novel factor VIIIa mimetic bispecific antibody, shows favorable safety and pharmacokinetics in healthy adults. (2023) pubmed
- In vitro effects of Mim8 and combined Mim8-bypassing therapy on thrombin generation, thromboelastography and fibrin clot ultrastructure. (2025) pubmed
- Model-informed drug development of Mim8 - a next-generation bispecific antibody for treatment of haemophilia A. (2025) pubmed
- In vitro effects of combining Mim8 with factor VIII, FVIIa, and activated prothrombin complex concentrates in thrombin generation assays. (2023) pubmed
- Anti-emicizumab antibodies do not cross-react with mim8 in vitro. (2023) pubmed
- The effect of a next generation factor VIII mimetic bispecific antibody (Mim8) on assays of factor VIII activity and thrombin generation. (2023) pubmed
- A novel next-generation FVIIIa mimetic, Mim8, has a favorable safety profile and displays potent pharmacodynamic effects: Results from safety studies in cynomolgus monkeys. (2022) pubmed
- FRONTIER1 multiple ascending dose extension: a safety, tolerability, pharmacokinetics, and pharmacodynamics study of Mim8 in people with hemophilia A. (2025) pubmed